Lab Reference Library / TGF-beta1 (Transforming Growth Factor Beta 1) Detox, Mold & CIRS

TGF-beta1 (Transforming Growth Factor Beta 1)

TGF-beta1 · TGFB1 · Transforming Growth Factor Beta 1

Reference range, optimal functional medicine levels, and why TGF-beta1 is a central mediator of fibrosis, immune dysregulation, and MSH suppression in CIRS, how biotoxin-driven TGF-beta1 elevation perpetuates the self-reinforcing inflammatory cascade of mold illness, and why losartan is used specifically to target it in step 8 of the Shoemaker protocol.

CIRS MarkerSpecialty Testing

NormalBelow 2,380 pg/mL

CIRS ThresholdAbove 2,380 pg/mL

Unitspg/mL

Protocol StepStep 8: Losartan

← Back to Lab Reference Library

Category: Detox, Mold & CIRS | Also known as: TGFB1, Transforming Growth Factor Beta 1, TGF-beta

1. What This Test Measures

TGF-beta1 (transforming growth factor beta 1) is a 25-kilodalton homodimeric cytokine produced by platelets, macrophages, T regulatory cells, endothelial cells, fibroblasts, and many other cell types. It is one of the most pleiotropic signaling molecules in human biology, with context-dependent effects that range from powerfully anti-inflammatory and wound-healing in acute settings to pro-fibrotic and immunosuppressive in chronic disease states. TGF-beta1 signals through the SMAD pathway and through non-canonical routes including MAPK, PI3K-AKT, and Rho-GTPase cascades, producing a wide spectrum of tissue responses depending on the cellular context and concurrent signaling environment.

In normal physiology, TGF-beta1 is essential: it promotes regulatory T cell (Treg) differentiation, suppresses autoreactive lymphocytes, coordinates wound repair, inhibits excessive immune activation after pathogen clearance, and regulates organ fibrosis during healing. The problem arises when TGF-beta1 is chronically elevated, as occurs in biotoxin illness (CIRS from mold, Lyme disease, and other environmental toxins), autoimmune disease flares, chronic fibrotic conditions, and malignancy. In these states, persistently elevated TGF-beta1 drives pathological fibrosis in lungs, kidneys, liver, and cardiac tissue, suppresses natural killer cell and cytotoxic T cell function (reducing antimicrobial and antitumor immunity), expands Treg populations beyond the physiological range (further dampening effective immune responses), and disrupts the regulatory relationship with MSH (alpha-melanocyte stimulating hormone) that is central to the CIRS framework.

In the Shoemaker CIRS protocol, TGF-beta1 is one of seven core inflammatory markers used to characterize the biotoxin immune response pattern. Its elevation reflects both the direct effect of biotoxin innate immune activation and the downstream consequence of MSH depletion, since MSH normally restrains TGF-beta1 production through hypothalamic regulatory circuits. This bidirectional relationship means TGF-beta1 elevation perpetuates the very MSH depletion that allowed it to rise, creating one of the self-perpetuating feedback loops that makes CIRS so refractory to treatment without a structured sequential protocol.

2. Reference Range and Optimal Levels

TGF-beta1 Level	Interpretation
Below 2,000 pg/mL	Optimal: normal immune regulatory function; no CIRS signal from this marker
2,000 to 2,380 pg/mL	Borderline: evaluate in clinical context; check other CIRS markers; consider repeat testing
Above 2,380 pg/mL	Elevated: CIRS-consistent; correlate with C4a, MSH, MMP-9, VEGF, VIP, and clinical exposure history
Above 10,000 pg/mL	Markedly elevated: aggressive biotoxin immune activation; treatment urgency high
Above 20,000 pg/mL	Severely elevated: severe CIRS or concurrent fibrotic disease; full clinical evaluation required

TGF-beta1 is not CIRS-specific. The same elevation pattern is seen in active pulmonary fibrosis, chronic kidney disease, Lyme disease, long COVID inflammatory syndrome, active autoimmune disease flares, and malignancy. Interpretation requires the full CIRS panel alongside a detailed clinical history of water-damaged building exposure, tick bites, or other biotoxin sources. A markedly elevated TGF-beta1 in a patient with no plausible biotoxin exposure history requires evaluation for fibrotic organ disease and cancer before CIRS is attributed.

3. TGF-beta1 in the CIRS Inflammatory Cascade

The self-perpetuating TGF-beta1 and MSH feedback loop is the central mechanism explaining why CIRS does not resolve spontaneously even after biotoxin exposure ends in genetically susceptible patients.

Biotoxins activate innate immune pattern recognition receptors (TLR4, TLR2, NLRPs) on macrophages and dendritic cells, triggering the release of pro-inflammatory cytokines including IL-1beta, TNF-alpha, IL-6, and TGF-beta1. The elevated TGF-beta1 then signals the hypothalamus to reduce MSH production through cytokine-mediated suppression of POMC processing in corticotroph and melanotroph cells. With MSH depleted, TGF-beta1 loses its primary hypothalamic regulator and rises further. The elevated TGF-beta1 simultaneously suppresses NK cell and cytotoxic T cell function, expanding Tregs, impairing antimicrobial immune responses, and creating the immune vulnerability to MARCoNS (multiply-antibiotic-resistant coagulase-negative staphylococci) colonization of the nasal passages that perpetuates the inflammatory signal even after environmental exposure ends. This cascade explains the treatment sequence in the Shoemaker protocol: each step must be completed before the next is effective because they address different nodes in the interlocking feedback loop.

4. Non-CIRS Causes of Elevated TGF-beta1

Fibrotic and Inflammatory Conditions

Idiopathic pulmonary fibrosis (IPF): TGF-beta1 is the primary fibrogenic driver in IPF; levels can be dramatically elevated and correlate with disease progression rate; pirfenidone (an FDA-approved antifibrotic) works in part by inhibiting TGF-beta1 signaling
Diabetic nephropathy: TGF-beta1 drives mesangial expansion, podocyte loss, and tubulointerstitial fibrosis in diabetic kidney disease; serum TGF-beta1 correlates with rate of GFR decline and proteinuria severity
Hepatic fibrosis and cirrhosis: TGF-beta1 from activated hepatic stellate cells drives collagen deposition and progressive liver fibrosis; elevated in all major etiologies including NAFLD, alcoholic liver disease, and viral hepatitis
Cardiac fibrosis: elevated in hypertensive heart disease, post-myocardial infarction remodeling, and cardiomyopathy; TGF-beta1-driven myocardial fibrosis reduces compliance and contributes to diastolic dysfunction

Infectious and Immune Conditions

Lyme disease and tick-borne coinfections: Borrelia burgdorferi and coinfections (Bartonella, Babesia, Ehrlichia) elevate TGF-beta1 through both direct immune activation and the CIRS mechanism in HLA-DR-susceptible patients; Lyme CIRS overlaps substantially with mold CIRS on the inflammatory marker panel
Post-COVID inflammatory syndrome (Long COVID): persistent TGF-beta1 elevation is documented in Long COVID, reflecting ongoing immune dysregulation and tissue-remodeling processes that persist after viral clearance; the CIRS framework has been proposed as a mechanism for Long COVID in susceptible patients
Active autoimmune disease: SLE, rheumatoid arthritis, Sjogren's syndrome, and inflammatory myopathies all elevate TGF-beta1 during active disease; interpretation requires concurrent autoimmune panel evaluation
Malignancy: many cancers produce TGF-beta1 as an immune evasion mechanism, suppressing anti-tumor cytotoxic T cell responses; markedly elevated TGF-beta1 in a patient without clear biotoxin or fibrotic disease history warrants oncology evaluation

5. The CIRS Treatment Sequence and TGF-beta1

Step 1: Eliminate ongoing biotoxin exposure. TGF-beta1 will not normalize while the patient remains in a water-damaged building or other biotoxin source. ERMI (Environmental Relative Moldiness Index) dust sampling of the home and workplace is the first investigative tool. Visual Contrast Sensitivity (VCS) testing provides rapid neurological screening. Patients must leave the environment before any downstream treatment can produce lasting results.
Step 2: Biotoxin binder therapy. Cholestyramine (CSM, 4g four times daily taken away from all medications and supplements) binds biotoxins in the enterohepatic circulation, interrupting the recirculation loop that keeps the innate immune system continuously activated. Welchol (colesevelam) is an alternative with a more favorable side effect profile for patients who cannot tolerate CSM. Binder therapy for 30 days is the first active treatment step and is the intervention most directly responsible for the initial C4a and TGF-beta1 reduction.
Step 3: Address MARCoNS. Multiply-antibiotic-resistant coagulase-negative staphylococci colonizing the deep nasal passages produce hemolysins that cleave and deplete MSH and sustain TGF-beta1 elevation even after biotoxin binder therapy. Nasal culture-directed treatment (typically BEG spray: Bactroban/Bacitracin/EDTA/Gentamicin) eradicates MARCoNS and allows MSH to begin recovering, which in turn reduces TGF-beta1 through restored hypothalamic regulation.
Step 4: Address androgen deficiency. DHEA and testosterone are often suppressed in CIRS from the hypothalamic dysregulation; low androgens impair TGF-beta1 counter-regulation and perpetuate immune imbalance.
Step 5: Correct ADH and osmolality dysregulation. Low ADH (antidiuretic hormone) from hypothalamic dysfunction causes polydipsia and dyselectrolytemia that compounds the inflammatory picture.
Step 6: Lower MMP-9. Elevated MMP-9 degrades the blood-brain barrier extracellular matrix; lowering it (through the low amylose diet and omega-3s) reduces neurological symptom burden.
Step 7: Lower C4a. Complement activation normalization with continued binder therapy and confirmed exposure elimination.
Step 8: Lower TGF-beta1 specifically. Losartan (an angiotensin II receptor blocker) has documented TGF-beta1-lowering activity beyond its blood pressure effects, acting through AT1R blockade to reduce TGF-beta1 transcription; typical CIRS dose is 25 to 50mg daily. This step addresses TGF-beta1 directly after upstream contributors have been treated.
Steps 9 through 11: VIP and final regulatory restoration. VIP nasal spray restores MSH, reduces MMP-9, raises VEGF, and normalizes pulmonary artery pressure. TGF-beta1 monitoring throughout confirms step-by-step progress.

6. How to Support TGF-beta1 Normalization

Primary CIRS Protocol

Remove from water-damaged environment: non-negotiable first step; no other intervention produces lasting TGF-beta1 normalization while exposure continues
Cholestyramine 4g four times daily: taken 30 minutes before meals; separated from all medications by at least 4 hours; continue for minimum 30 days with repeat TGF-beta1 and C4a monitoring to confirm response
Welchol 625mg three tablets twice daily: alternative binder; better tolerated than cholestyramine; slightly less potent for mycotoxin binding
Losartan 25 to 50mg daily: specifically targets TGF-beta1 after upstream steps completed; monitor blood pressure; use with caution in patients already on antihypertensives
MARCoNS eradication: BEG nasal spray (or EDTA spray as alternative) directed by nasal culture sensitivity; retreating without culture-guided therapy risks selecting for further resistance

Adjunctive Nutritional Support

Curcumin (high-bioavailability form, 500 to 1,000mg daily): inhibits TGF-beta1 signaling through SMAD pathway suppression and NF-kB inhibition; evidence in fibrosis models across multiple organ systems; use phosphatidylcholine complex or nanoparticle formulation for adequate absorption
Omega-3 fatty acids (3 to 4g EPA and DHA daily): EPA inhibits TGF-beta1-driven fibroblast activation through PPARgamma signaling; reduces fibrotic response in lung, kidney, and cardiac tissue models; anti-fibrotic evidence across multiple organ systems
Vitamin D optimization (60 to 80 ng/mL): vitamin D receptor (VDR) signaling directly suppresses TGF-beta1 gene transcription through VDR binding to the TGF-beta1 promoter; deficiency exacerbates TGF-beta1 elevation in CIRS and autoimmune conditions
Quercetin (500 to 1,000mg daily): inhibits TGF-beta1-induced SMAD2/3 phosphorylation; reduces epithelial-mesenchymal transition driven by TGF-beta1; additionally reduces mast cell histamine release relevant in CIRS
NAC (N-acetylcysteine, 600mg twice daily): reduces oxidative stress that amplifies TGF-beta1 signaling; supports glutathione production for mycotoxin detoxification

Lifestyle Foundations

Sleep optimization: TGF-beta1 is regulated by circadian and sleep-dependent immune rhythms; chronic sleep deprivation amplifies the pro-inflammatory cytokine environment that sustains TGF-beta1; target 7 to 9 hours in a dark, cool, mold-free environment
Low amylose diet: the Shoemaker protocol recommends avoiding high-amylose starches (potatoes, wheat, rice, corn) during CIRS treatment; amylose may stimulate leptin, which drives MMP-9 and amplifies TGF-beta1 in susceptible patients; emphasize non-starchy vegetables, lean protein, and healthy fats
Avoid immune-suppressing substances: alcohol suppresses NK cell function and amplifies TGF-beta1 through hepatic stellate cell activation; eliminate or minimize during active CIRS treatment
Moderate aerobic exercise: reduces systemic inflammation and supports immune regulatory balance; avoid overtraining, which can spike TGF-beta1 through muscle damage and excessive cortisol; target 150 minutes weekly of moderate-intensity activity
HEPA air filtration: high-efficiency particulate air filtration in the home reduces ongoing mold spore exposure during and after remediation; MERV-13 or higher in HVAC systems; standalone HEPA units in bedroom

7. Related Lab Tests

MSHTGF-beta1 and MSH Are Inversely Regulated in CIRS

→

C4aComplement Activation Companion; the Primary CIRS Upstream Marker

→

MMP-9Tissue-Degrading Enzyme; Addressed Before TGF-beta1 in Protocol

→

VEGFCapillary Hypoperfusion Companion CIRS Marker

→

VIPFinal Regulatory Neuropeptide; Restores MSH and Reduces TGF-beta1

→

Mycotoxin PanelDirect Biotoxin Exposure Confirmation Alongside Immune Response Markers

→

8. Clinical Perspective

Clinical Perspective

TGF-beta1 is the marker that tells me how far the immune dysregulation has progressed in a CIRS patient, because it sits at the intersection of the fibrotic, immunosuppressive, and neurological arms of the biotoxin response simultaneously. When I see TGF-beta1 of 14,000 pg/mL alongside C4a of 32,000 ng/mL and MSH of 18 pg/mL, I am looking at a patient whose innate immune system has been in continuous activation for long enough that the downstream regulatory peptides are completely depleted and the fibrotic cascade is running without a brake. The treatment sequence matters as much as the diagnosis at that point. Every step in the Shoemaker protocol exists because each upstream problem prevents the downstream intervention from working: you cannot effectively raise MSH until MARCoNS is cleared, you cannot lower TGF-beta1 with losartan until C4a has been addressed, and you cannot achieve lasting benefit from VIP until TGF-beta1 is controlled. The numbers guide the sequence, and the sequence is the treatment. Trying to skip steps because a patient is impatient is the most common reason CIRS patients cycling through treatments fail to recover.

Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma

9. Frequently Asked Questions

What does elevated TGF-beta1 indicate in CIRS?

Elevated TGF-beta1 above 2,380 pg/mL in the context of CIRS evaluation indicates that the biotoxin-driven innate immune response has produced a pro-fibrotic, immunosuppressive inflammatory state. It reflects that the MSH regulatory brake on TGF-beta1 has been released by biotoxin-driven hypothalamic suppression. In CIRS, TGF-beta1 elevation perpetuates immune dysregulation, expands Tregs, impairs NK cell function, and drives MARCoNS vulnerability. It requires the full sequential treatment protocol rather than isolated suppression.

Why will TGF-beta1 not normalize without removing the biotoxin source?

Biotoxins that cannot be cleared through normal antibody-mediated immune mechanisms (due to HLA-DR genetic susceptibility) undergo continuous enterohepatic recirculation, stimulating repeated innate immune activation with every gut transit cycle. This continuous activation maintains the TGF-beta1 elevation regardless of any downstream suppression attempt. Cholestyramine and welchol interrupt this cycle by binding biotoxins in the bile before reabsorption, but only after confirmed exposure elimination. Treating TGF-beta1 without eliminating the source is equivalent to treating smoke inhalation without leaving the burning building.

How long does it take for TGF-beta1 to normalize with CIRS treatment?

TGF-beta1 response varies by biotoxin burden, exposure duration, HLA-DR genotype, and protocol compliance. With confirmed exposure elimination and cholestyramine therapy, initial TGF-beta1 reduction is typically measurable within 30 days. Reaching below 2,380 pg/mL may take 3 to 6 months of sequential protocol completion. Patients with very high starting values (above 10,000 pg/mL) or with concurrent MARCoNS colonization may require 6 to 12 months of structured treatment. Repeat measurement every 30 to 60 days tracks progress and guides protocol advancement.

Is TGF-beta1 elevation specific to mold illness?

No. TGF-beta1 is elevated in many conditions beyond mold CIRS: idiopathic pulmonary fibrosis, diabetic nephropathy, hepatic fibrosis, Lyme disease CIRS, Long COVID inflammatory syndrome, active autoimmune diseases, and malignancy. The CIRS interpretation of elevated TGF-beta1 requires the full panel context (elevated C4a, low MSH, elevated MMP-9, low VEGF and VIP) alongside a documented history of water-damaged building exposure. TGF-beta1 elevation without other CIRS markers and without plausible biotoxin exposure requires evaluation for fibrotic organ disease and cancer.

What is the role of losartan in TGF-beta1 reduction?

Losartan (an angiotensin II receptor blocker) has documented TGF-beta1-lowering activity through AT1R blockade that reduces TGF-beta1 gene transcription independently of its blood pressure effects. In the Shoemaker CIRS protocol, losartan at 25 to 50mg daily is used specifically in step 8 to address persistent TGF-beta1 elevation after upstream steps (binders, MARCoNS eradication, androgen correction, ADH normalization, and MMP-9 and C4a reduction) have been completed. Using losartan before upstream steps are addressed produces limited benefit because the biotoxin-driven TGF-beta1 stimulus remains active.

Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.

TGF-beta1 elevation in CIRS is both a consequence and a perpetuator of biotoxin immune dysregulation. Addressing it requires the full sequential protocol, not isolated suppression.

TGF-beta1 normalization requires a structured sequential approach to CIRS treatment. Schedule a consultation for a comprehensive CIRS evaluation and treatment planning session.

Schedule a Consultation

Medical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.